Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116206 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL1126722 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL7995962 | 0.83 | ALDH1A1 (0.61) | ALDH1A1TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL29391169 | 0.83 | ALDH1A1 (0.61) | ALDH1A1TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL18185050 | 0.83 | ALDH1A1 (0.61) | ALDH1A1TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL3420889 | 0.82 | TDP1 (0.54) | ALDH1A1TDP1NPC1RAB9AKMT2A | |
| SCHEMBL27638672 | 0.81 | ALDH1A1 (0.43) | ALDH1A1TDP1L3MBTL1HTTGAA | |
| SCHEMBL11048268 | 0.81 | ALDH1A1 (0.57) | ALDH1A1TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL1126997 | 0.81 | ALDH1A1 (0.57) | ALDH1A1TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL942459 | 0.81 | ALDH1A1 (0.57) | ALDH1A1TDP1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713313-A2 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | Springworks Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4660185-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| US-12384751-B2 | Allosteric activators of the ALPHA1A-adrenergic receptor | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240417398-A1 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. | 2024-12-19 | — | — | US | disclosed |
| WO-2024238763-A2 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024233900-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-3958851-B1 | ALLOSTERIC ACTIVATORS OF THE ALPHA IA-ADRENERGIC RECEPTOR | CLEVELAND CLINIC FOUND (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024159288-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-08-08 | — | — | WO | disclosed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| US-20030069226-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-10 | — | — | US | disclosed |
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| WO-2002076982-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-10-03 | — | — | WO | disclosed |
| EP-1236717-A1 | OXIME O-ETHER COMPOUNDS AND FUNGICIDES FOR AGRICULTURAL AND HORTICULTURAL USE | NIPPON SODA CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006255-A2 | HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001044184-A1 | SYNTHESIS OF INDOLE-CONTAINING SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| US-4668686-A | 1,3-DIHYDRO-2H-IMIDAZO/4,5-B/QUINOLINE-2-ONES | BRISTOL-MYERS COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| US-4310527-A | DISORDERS OF CAROIAC RHYTHM AND CORONARY HEART DISEASES AND HYDPERTENSION | CIBA-GEIGY CORPORATION (US) | 1982-01-12 | — | — | US | disclosed |
| US-4140789-A | ADRENERGIC BLOCKING AGENTS, CARDIOTONIC, ANTIARRHYTHMIA, HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069226-A1 | Non-nucleoside reverse transcriptase inhibitors | RCOR1, CBR1, SUB1 | ALDH1A1 1568/4885TDP1 439/4885L3MBTL1 212/4885 |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | ALDH1A1 783/4885TDP1 3616/4885L3MBTL1 4066/4885 |
| US-12384751-B2 | Allosteric activators of the ALPHA1A-adrenergic receptor | ADRA1A, ADRB1, ADRA1D | ALDH1A1 145/4885TDP1 987/4885L3MBTL1 1740/4885 |
| US-20240417398-A1 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | ALDH1A1 3016/4885TDP1 680/4885L3MBTL1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.